A newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis.
Human drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by three medical centres. They call to establish documentation standards for IBs/preclinical dossiers.
French Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio with a tumour microenvironment modifier that reactivates effector T cell responses.
French allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis.
Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients.
Japanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April.
Roche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its
to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect of Factor VIII which lack patients with hemophilia A.
More than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies.
Belgian nanobody maker Ablynx IL-6 receptor blocker vobarilizumab didnt met the primary endpoint of dose response at 24 weeks in a Phase II study enroling 312 patients with severe, active seropositive systemic lupus erythematosus (SLE).
Antibody specialist MorphoSys AG has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed Nasdaq offering of American Depositary Shares (ADS)